K Holli

Summary

Affiliation: Tampere University Hospital
Country: Finland

Publications

  1. ncbi Low biologic aggressiveness in breast cancer in women using hormone replacement therapy
    K Holli
    Department of Oncology, University Hospital of Tampere, Institute of Medical Technology, University of Tampere, Finland
    J Clin Oncol 16:3115-20. 1998
  2. ncbi Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy
    T Kuukasjärvi
    Department of Pathology, Tampere University Hospital, University of Tampere, Finland
    J Clin Oncol 14:2584-9. 1996
  3. ncbi Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer
    T A Järvinen
    Laboratory of Cancer Genetics, Tampere University Hospital and Institute of Medical Technology, University of Tampere, Finland
    Br J Cancer 77:2267-73. 1998
  4. ncbi Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer
    T A Järvinen
    Laboratory of Cancer Biology, Institute of Medical Technology, Tampere University and University Hospital, Tampere, Finland
    Am J Pathol 156:29-35. 2000
  5. ncbi Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer
    A Jukkola
    Department of Oncology, University of Oulu, Finland
    Anticancer Res 21:2873-6. 2001
  6. ncbi Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study
    J Lundin
    Department of Oncology, University of Helsinki, Helsinki, Finland
    J Clin Oncol 19:28-36. 2001
  7. ncbi Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer
    H Joensuu
    Department of Oncology, Helsinki University Central Hospital, Finland
    Breast Cancer Res Treat 63:225-34. 2000
  8. ncbi c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease
    A Jukkola
    Department of Oncology, University of Oulu, Finland
    Eur J Cancer 37:347-54. 2001
  9. ncbi Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient--fact or fallacy
    K Holli
    Department of Oncology, University Hospital of Tampere, Pikonlinna, Finland
    Br J Cancer 71:124-7. 1995
  10. ncbi Information and communication in the context of a clinical trial
    P Hietanen
    Department of Oncology, University Hospital of Helsinki, PO Box 180, FIN 00029, Finland
    Eur J Cancer 36:2096-104. 2000

Collaborators

  • H Joensuu
  • M Hakama
  • G Blanco
  • J Cuzick
  • Y Soini
  • T Turpeenniemi-Hujanen
  • J Lundin
  • A R Aro
  • T Visakorpi
  • R Kokko
  • M Parkkari
  • Ritva Järvenpää
  • H Eerola
  • Tarja Korhonen
  • A Jukkola
  • T Kuukasjärvi
  • E L Alarmo
  • T A Järvinen
  • H Huhtala
  • R Asola
  • Ioannis Tsougos
  • K Pääkkönen
  • L Sarantaus
  • R Bloigu
  • R Krahe
  • P Vehmanen
  • H Nevanlinna
  • J Kere
  • P Vahteristo
  • P Hietanen
  • A Kallioniemi
  • E-L Alarmo
  • Panayiotis Mavroidis
  • Kyriaki Theodorou
  • A T Ojala
  • J Rajala
  • J Isola
  • Bengt K Lind
  • Constantin Kappas
  • H Kaariainen
  • E Vauramo
  • J Risteli
  • E R Savolainen
  • J Ignatius
  • A Hartikainen
  • R Valavaara
  • V Ollikainen
  • S Sauramo
  • A Borg
  • R Butzow
  • T Kainu
  • J Hartikainen
  • C Blomqvist
  • K Syrjakoski
  • E Holmberg
  • M Pelto-Huikko
  • V Launonen
  • R Winqvist
  • M Ryynanen
  • P Absetz
  • T Lopponen
  • E Gillanders
  • K Rapakko
  • P Huusko
  • O P Kallioniemi
  • A Mannermaa
  • B Wasteson Arver
  • J J Isola
  • H Helin
  • J Kononen

Detail Information

Publications23

  1. ncbi Low biologic aggressiveness in breast cancer in women using hormone replacement therapy
    K Holli
    Department of Oncology, University Hospital of Tampere, Institute of Medical Technology, University of Tampere, Finland
    J Clin Oncol 16:3115-20. 1998
    ..We sought to explain this by a comparison of indicators of tumor aggressiveness in patients who received HRT with those in patients who did not...
  2. ncbi Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy
    T Kuukasjärvi
    Department of Pathology, Tampere University Hospital, University of Tampere, Finland
    J Clin Oncol 14:2584-9. 1996
    ..We studied how often hormone receptor status changes between primary and recurrent tumors and whether such a change might explain unresponsiveness to endocrine therapy...
  3. ncbi Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer
    T A Järvinen
    Laboratory of Cancer Genetics, Tampere University Hospital and Institute of Medical Technology, University of Tampere, Finland
    Br J Cancer 77:2267-73. 1998
    ..Among the prognostic biomarkers, overexpression of c-erbB2 oncogene and negative ER may have predictive value in epirubicin therapy in patients with advanced breast cancer...
  4. ncbi Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer
    T A Järvinen
    Laboratory of Cancer Biology, Institute of Medical Technology, Tampere University and University Hospital, Tampere, Finland
    Am J Pathol 156:29-35. 2000
    ..The independent predictive value of ERbeta remains to be established...
  5. ncbi Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer
    A Jukkola
    Department of Oncology, University of Oulu, Finland
    Anticancer Res 21:2873-6. 2001
    ..also a factor for poorer survivaL Tumor size, malignancy grade and progesterone receptors were shown in multivariate analysis to be predictors of recurrence and tumor size and PINP and progesterone receptors to be predictors of survivaL..
  6. ncbi Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study
    J Lundin
    Department of Oncology, University of Helsinki, Helsinki, Finland
    J Clin Oncol 19:28-36. 2001
    ..To investigate the influence of routinely performed histologic grading on breast cancer outcome prediction and patient selection for adjuvant therapy...
  7. ncbi Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer
    H Joensuu
    Department of Oncology, Helsinki University Central Hospital, Finland
    Breast Cancer Res Treat 63:225-34. 2000
    ..In conclusion, we found no major differences between 40 mg toremifene and 20 mg of tamoxifen in their effect on the serum lipid levels, which return to the pretreatment levels within 6 months after cessation of therapy...
  8. ncbi c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease
    A Jukkola
    Department of Oncology, University of Oulu, Finland
    Eur J Cancer 37:347-54. 2001
    ..Positivity for the c-erbB-2 is a poor prognostic factor in breast cancer, but it also emerges as predictive of the response to hormonal or chemotherapy treatment once the disease has recurred...
  9. ncbi Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient--fact or fallacy
    K Holli
    Department of Oncology, University Hospital of Tampere, Pikonlinna, Finland
    Br J Cancer 71:124-7. 1995
    ..Variation in the lag between the diagnostic confirmation and the operation of the patient affects the evaluation of such an effect and may account for the inconsistent results reported so far...
  10. ncbi Information and communication in the context of a clinical trial
    P Hietanen
    Department of Oncology, University Hospital of Helsinki, PO Box 180, FIN 00029, Finland
    Eur J Cancer 36:2096-104. 2000
    ..Information should be modified for older and less-educated patients. The needs of the patients when offered participation in a clinical trial are clear information, enough time to consider the options and psychological support...
  11. ncbi Hereditary breast cancer
    K Holli
    Department of Oncology, Tampere University Hospital, Finland
    Acta Oncol 38:29-32. 1999
    ..Genetic information on breast cancer is, however, still limited and although the tests that are now available can be beneficial, they also carry some risks and limitations...
  12. ncbi High cell proliferation activity determined by DNA flow cytometry and prognosis in epidermoid lung carcinoma
    T Visakorpi
    Department of Clinical Chemistry, Tampere University Hospital, School of Public Health, University of Tampere, Finland
    Acta Oncol 34:605-9. 1995
    ..Neither DNA aneuploidy nor SPF was associated with survival in small-cell lung carcinoma. In conclusion, SPF is an independent prognostic factor in epidermoid lung carcinoma...
  13. ncbi Bone morphogenetic protein 7 expression associates with bone metastasis in breast carcinomas
    E L Alarmo
    Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland
    Ann Oncol 19:308-14. 2008
    ..We recently showed that bone morphogenetic protein 7 (BMP7) is overexpressed in primary breast tumors. Here we explored the clinical significance of BMP7 expression in breast cancer...
  14. ncbi Tamoxifen versus toremifene in the adjuvant treatment of breast cancer
    K Holli
    Department of Medicine, University Hospital and University of Tampere, Finland
    Eur J Cancer 38:S37-8. 2002
  15. ncbi Intensity of diagnostic and treatment activities during the end of life of patients with advanced breast cancer
    R Asola
    Department of Oncology, Central Hospital of Satakunta, Sairaalantie 3, Fin 28500 Pori, Finland
    Breast Cancer Res Treat 100:77-82. 2006
    ..Resources devoted to diagnostic investigations and treatment of cancer in terminally ill patients could be better used for their care. This would be more likely to improve patients' quality of life and save resources...
  16. ncbi Clinical validation of the LKB model and parameter sets for predicting radiation-induced pneumonitis from breast cancer radiotherapy
    Ioannis Tsougos
    Phys Med Biol 51:L1-9. 2006
    ....
  17. ncbi Follow-up cost of breast cancer patients with localized disease after primary treatment: a randomized trial
    R Kokko
    Department of Oncology, Central Hospital of Kanta Hame, Hameenlinna, Finland
    Breast Cancer Res Treat 93:255-60. 2005
    ..2 times...
  18. ncbi A comparison of the biological and clinical features of invasive lobular and ductal carcinomas of the breast
    T Korhonen
    Department of Palliative Medicine, Tampere University Hospital, and School of Medicine, Tampere, Finland
    Breast Cancer Res Treat 85:23-9. 2004
    ..In conclusion, since ILC cancers are more often hormone receptor-positive, there is a good option to adjuvant endocrine therapy with present and future preparations, this possibly leading to improvement in OS...
  19. ncbi Role of chest X-ray in diagnosis of the first breast cancer relapse: a randomized trial
    R Kokko
    Department of Oncology, Central Hospital of Kanta Hame, Hameenlinna, Finland
    Breast Cancer Res Treat 81:33-9. 2003
    ..Routine chest X-ray in the follow-up of breast cancer patient is evidently of little use and is not likely to be of benefit to the patient in terms of disease free survival or overall survival as compared to the spontaneous schedule...
  20. ncbi Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study
    M Parkkari
    Department of Ophthalmology, Tampere University Hospital, PO Box 2000, 33501 Tampere, Finland
    Acta Ophthalmol Scand 81:495-9. 2003
    ..The aim of this study was to monitor the ocular side-effects of both of these commonly used anti-oestrogens...
  21. ncbi Ca 15-3 in the follow-up of localised breast cancer: a prospective study
    R Kokko
    Department of Oncology and Central Hospital of Central Finland, Jyväskylä and University of Tampere, Tampere, Finland
    Eur J Cancer 38:1189-93. 2002
    ..The positive predictive value especially remained poor in patients with a relatively good prognosis. Our results confirm that the test is not suitable alone for breast cancer follow-up...
  22. ncbi Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland
    L Sarantaus
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland
    Eur J Hum Genet 8:757-63. 2000
    ..An isolated population with known history and multiple local founder effects in multigenic disease may offer distinct advantages also for mapping novel predisposing genes...
  23. ncbi Involvement of BRCA1 and BRCA2 in breast cancer in a western Finnish sub-population
    K Pääkkönen
    Department of Medical Genetics, Haartman Institute, University of Helsinki, Helsinki, Finland
    Genet Epidemiol 20:239-46. 2001
    ..The geographical clustering of breast cancer cases was not explained by BRCA1 or BRCA2 genes...